Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrea Lorenzon is active.

Publication


Featured researches published by Andrea Lorenzon.


Blood | 2011

In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions

Chiara Agostinis; Stefania Biffi; Chiara Garrovo; Paolo Durigutto; Andrea Lorenzon; Alpan Bek; Roberta Bulla; Claudia Grossi; Maria Orietta Borghi; Pier Luigi Meroni; Francesco Tedesco

In vitro studies have documented β2 glycoprotein I (β2GPI) binding to endothelial cells (ECs) and trophoblast using antiphospholipid antibodies. The in vivo binding of β2GPI to these cells and the conditions that favor their interaction have not been investigated. We analyzed the in vivo distribution of cyanine 5.5-labeled β2GPI in mice and evaluated the effect of pregnancy and circulating antibodies on its tissue localization. The signal was detected in the liver by whole body scan and ex vivo analysis. The β2GPI failed to bind to the vascular endothelium and reacted only with the ECs of uterine vessels. In pregnant mice the protein was localized on ECs and trophoblast at the embryo implantation sites. Immunized mice showed a similar β2GPI biodistribution to naive mice but the immunized pregnant animals exhibited a significant increase in fetal loss associated with C3 and C9 deposition at the implantation sites. Treatment of mice with LPS after β2GPI-Cy5.5 injection promoted protein localization on gut and brain ECs associated with IgG, C1q, and C9 deposition in immunized mice. These findings indicate that β2GPI binding to EC requires priming with pro-inflammatory factors which is not needed for uterine and placental localization probably dependent on hormonal changes.


Journal of Synchrotron Radiation | 2015

Functionalized synchrotron in-line phase-contrast computed tomography: a novel approach for simultaneous quantification of structural alterations and localization of barium-labelled alveolar macrophages within mouse lung samples

Christian Dullin; Simeone Dal Monego; Emanuel Larsson; Sara Mohammadi; Martin Krenkel; Chiara Garrovo; Stefania Biffi; Andrea Lorenzon; Andrea Markus; Joanna Napp; Tim Salditt; Agostino Accardo; Frauke Alves; Giuliana Tromba

This study presents an approach to increase the sensitivity of lung computed tomography (CT) imaging by utilizing in-line phase contrast CT in combination with single-distance phase-retrieval algorithms and a dedicated image-processing regime. As demonstrated here, functional CT imaging can be achieved for the assessment of both structural alterations in asthmatic mouse lung tissue and the accumulation pattern of instilled barium-sulfate-labelled macrophages in comparison with healthy controls.


Journal of Synchrotron Radiation | 2014

Quantitative evaluation of a single‐distance phase‐retrieval method applied on in‐line phase‐contrast images of a mouse lung

Sara Mohammadi; Emanuel Larsson; Frauke Alves; Simeone Dal Monego; Stefania Biffi; Chiara Garrovo; Andrea Lorenzon; Giuliana Tromba; Christian Dullin

Quantitative analysis concerning the application of a single-distance phase-retrieval algorithm on in-line phase-contrast images of a mouse lung at different sample-to-detector distances is presented.


Nanotechnology | 2017

Cubosomes for in vivo fluorescence lifetime imaging

Stefania Biffi; Laura Andolfi; Claudia Caltagirone; Chiara Garrovo; Angela Maria Falchi; Vito Lippolis; Andrea Lorenzon; Paolo Macor; Valeria Meli; Maura Monduzzi; Marc Obiols-Rabasa; Luca Petrizza; Luca Prodi; Antonella Rosa; Judith Schmidt; Yeshayahu Talmon; Sergio Murgia

Herein we provided the first proof of principle for in vivo fluorescence optical imaging application using monoolein-based cubosomes in a healthy mouse animal model. This formulation, administered at a non-cytotoxic concentration, was capable of providing both exogenous contrast for NIR fluorescence imaging with very high efficiency and chemospecific information upon lifetime analysis. Time-resolved measurements of fluorescence after the intravenous injection of cubosomes revealed that the dye rapidly accumulated mainly in the liver, while lifetimes profiles obtained in vivo allowed for discriminating between free dye or dye embedded within the cubosome nanostructure after injection.


International Journal of Molecular Imaging | 2013

In Vivo Tracking of Murine Adipose Tissue-Derived Multipotent Adult Stem Cells and Ex Vivo Cross-Validation

Chiara Garrovo; Natascha Bergamin; Dave Bates; Daniela Cesselli; Antonio Paolo Beltrami; Andrea Lorenzon; Roberto Ferrari; Carlo Alberto Beltrami; Vito Lorusso; Stefania Biffi

Stem cells are characterized by the ability to renew themselves and to differentiate into specialized cell types, while stem cell therapy is believed to treat a number of different human diseases through either cell regeneration or paracrine effects. Herein, an in vivo and ex vivo near infrared time domain (NIR TD) optical imaging study was undertaken to evaluate the migratory ability of murine adipose tissue-derived multipotent adult stem cells [mAT-MASC] after intramuscular injection in mice. In vivo NIR TD optical imaging data analysis showed a migration of DiD-labelled mAT-MASC in the leg opposite the injection site, which was confirmed by a fibered confocal microendoscopy system. Ex vivo NIR TD optical imaging results showed a systemic distribution of labelled cells. Considering a potential microenvironmental contamination, a cross-validation study by multimodality approaches was followed: mAT-MASC were isolated from male mice expressing constitutively eGFP, which was detectable using techniques of immunofluorescence and qPCR. Y-chromosome positive cells, injected into wild-type female recipients, were detected by FISH. Cross-validation confirmed the data obtained by in vivo/ex vivo TD optical imaging analysis. In summary, our data demonstrates the usefulness of NIR TD optical imaging in tracking delivered cells, giving insights into the migratory properties of the injected cells.


International Journal of Nanomedicine | 2015

Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies

Sara Capolla; Chiara Garrovo; Sonia Zorzet; Andrea Lorenzon; Enrico Rampazzo; Ruben Spretz; Gabriele Pozzato; Luis Nuñez; Claudio Tripodo; Paolo Macor; Stefania Biffi

The expectations of nanoparticle (NP)-based targeted drug delivery systems in cancer, when compared with convectional therapeutic methods, are greater efficacy and reduced drug side effects due to specific cellular-level interactions. However, there are conflicting literature reports on enhanced tumor accumulation of targeted NPs, which is essential for translating their applications as improved drug-delivery systems and contrast agents in cancer imaging. In this study, we characterized biodegradable NPs conjugated with an anti-CD20 antibody for in vivo imaging and drug delivery onto tumor cells. NPs’ binding specificity mediated by anti-CD20 antibody was evaluated on MEC1 cells and chronic lymphocytic leukemia patients’ cells. The whole-body distribution of untargeted NPs and anti-CD20 NPs were compared by time-domain optical imaging in a localized human/mouse model of B-cell malignancy. These studies provided evidence that NPs’ functionalization by an anti-CD20 antibody improves tumor pharmacokinetic profiles in vivo after systemic administration and increases in vivo imaging of tumor mass compared to non-targeted NPs. Together, drug delivery and imaging probe represents a promising theranostics tool for targeting B-cell malignancies.


Clinical Science | 2018

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse

Stella Bernardi; Barbara Toffoli; Veronica Tisato; Fleur Bossi; Stefania Biffi; Andrea Lorenzon; Giorgio Zauli; Paola Secchiero; Bruno Fabris

Recent studies suggest that a circulating protein called TRAIL (TNF-related apoptosis inducing ligand) may have an important role in the treatment of type 2 diabetes. It has been shown that TRAIL deficiency worsens diabetes and that TRAIL delivery, when it is given before disease onset, slows down its development. The present study aimed at evaluating whether TRAIL had the potential not only to prevent, but also to treat type 2 diabetes. Thirty male C57BL/6J mice were randomized to a standard or a high-fat diet (HFD). After 4 weeks of HFD, mice were further randomized to receive either placebo or TRAIL, which was delivered weekly for 8 weeks. Body weight, food intake, fasting glucose, and insulin were measured at baseline and every 4 weeks. Tolerance tests were performed before drug randomization and at the end of the study. Tissues were collected for further analyses. Parallel in vitro studies were conducted on HepG2 cells and mouse primary hepatocytes. TRAIL significantly reduced body weight, adipocyte hypertrophy, free fatty acid levels, and inflammation. Moreover, it significantly improved impaired glucose tolerance, and ameliorated non-alcoholic fatty liver disease (NAFLD). TRAIL treatment reduced liver fat content by 47% in vivo as well as by 45% in HepG2 cells and by 39% in primary hepatocytes. This was associated with a significant increase in liver peroxisome proliferator-activated receptor (PPAR) γ (PPARγ) co-activator-1 α (PGC-1α) expression both in vivo and in vitro, pointing to a direct protective effect of TRAIL on the liver. The present study confirms the ability of TRAIL to significantly attenuate diet-induced metabolic abnormalities, and it shows for the first time that TRAIL is effective also when administered after disease onset. In addition, our data shed light on TRAIL therapeutic potential not only against impaired glucose tolerance, but also against NAFLD.


Biomedical Physics & Engineering Express | 2015

Quantification of structural alterations in lung disease—a proposed analysis methodology of CT scans of preclinical mouse models and patients

Emanuel Larsson; Giuliana Tromba; Kajsa Uvdal; Agostino Accardo; Simeone Dal Monego; Stefania Biffi; Chiara Garrovo; Andrea Lorenzon; Christian Dullin

In this paper we have established a general investigative methodology for quantitative computed tomography (CT) lung image analysis in the sagittal, coronal and transversal orientation of lungs wit ...


20th European Congress of Endocrinology | 2018

Effects of TRAIL delivery on an experimental model of type 2 diabetes and diabetic nephropathy

Stella Bernardi; Barbara Toffoli; Veronica Tisato; Andrea Lorenzon; Giorgio Zauli; Paola Secchiero; Bruno Fabris


18th European Congress of Endocrinology | 2016

TRAIL treatment reduces high-fat diet-induced hyperglycemia and hyperinsulinemia

Stella Bernardi; Fleur Bossi; Veronica Tisato; Stefania Biffi; Andrea Lorenzon; Barbara Toffoli; Giorgio Zauli; Paola Secchiero; Bruno Fabris

Collaboration


Dive into the Andrea Lorenzon's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christian Dullin

Elettra Sincrotrone Trieste

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Giuliana Tromba

Elettra Sincrotrone Trieste

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge